Predictive medication adherence analytic solutions
This article was originally published in Start Up
A team of public health and clinical outcomes experts has developed a suite of analytic software tools to predict – they claim as early as the first time a patient takes a new medicine – which patients will likely need interventions to remain adherent and to recommend interventions that will improve adherence as efficiently as possible. These experts launched RxAnte Inc. to commercialize their data analytics solution that enables users to analyze large data sets and drill down from the population level to the individual patient level. They hope to increase the clinical outcomes and economic returns from effective interventions by “fitting” them to the right patients at the right time.
You may also be interested in...
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.
Fueled by a series of strategic acquisitions, Patheon hopes to become the biopharma industry’s first single-source, end-to-end manufacturing service provider.
The demands of building new biotechs can take their toll, yet Alan Crane wears his 52 years and over two decades of high-risk biotech start-up investing lightly. He's built an exceptional number of companies during his tenure at Polaris, many of which have proved to be among the industry’s more successful emerging ventures.